Generalised anxiety disorder

被引:229
作者
Tyrer, Peter [1 ]
Baldwin, David
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Psychol Med, Div Neurosci & Mental Hlth, London W6 8RP, England
[2] Univ Southampton, Clin Neurosci Div, Sch Med, Southampton SO14 0YG, Hants, England
基金
英国惠康基金;
关键词
D O I
10.1016/S0140-6736(06)69865-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Generalised anxiety disorder is a persistent and common disorder, in which the patient has unfocused worry and anxiety that is not connected to recent stressful events, although it can be aggravated by certain situations. This disorder is twice as common in women than it is in men. Generalised anxiety disorder is characterised by feelings of threat, restlessness, irritability, sleep disturbance, and tension, and symptoms such as palpitations, dry mouth, and sweating. These symptoms are recognised as part of the anxiety syndrome rather than independent complaints. The symptoms overlap greatly with those of other common mental disorders and we could regard the disorder as part of a spectrum of mood and related disorders rather than an independent disorder. Generalised anxiety disorder has a relapsing course, and intervention rarely results in complete resolution of symptoms, but in the short term and medium term, effective treatments include psychological therapies, such as cognitive behavioural therapy; self-help approaches based on cognitive behavioural, therapy principles; and pharmacological treatments, mainly selective serotonin reuptake inhibitors.
引用
收藏
页码:2156 / 2166
页数:11
相关论文
共 141 条
[11]   Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology [J].
Baldwin, DS ;
Anderson, IM ;
Nutt, DJ ;
Bandelow, B ;
Bond, A ;
Davidson, JRT ;
den Boer, JA ;
Fineberg, NA ;
Knapp, M ;
Scott, J ;
Wittchen, HU .
JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (06) :567-596
[12]   Evidence-based pharmacotherapy of generalized anxiety disorder [J].
Baldwin, DS ;
Polkinghorn, C .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2005, 8 (02) :293-302
[13]  
Ballenger JC, 2001, J CLIN PSYCHIAT, V62, P11
[14]  
Bandelow Borwin, 2002, World J Biol Psychiatry, V3, P171, DOI 10.3109/15622970209150621
[15]  
Bielski Robert J, 2005, Ann Clin Psychiatry, V17, P65, DOI 10.1080/10401230590932326
[16]   The validity of the Hospital Anxiety and Depression Scale - An updated literature review [J].
Bjelland, I ;
Dahl, AA ;
Haug, TT ;
Neckelmann, D .
JOURNAL OF PSYCHOSOMATIC RESEARCH, 2002, 52 (02) :69-77
[17]  
Bower P, 2001, BRIT J GEN PRACT, V51, P838
[18]  
BOYD JH, 1984, ARCH GEN PSYCHIAT, V41, P983
[19]   Adjunctive risperidone in generalized anxiety disorder: A double-blind, placebo-controlled study [J].
Brawman-Mintzer, O ;
Knapp, RG ;
Nietert, PJ .
JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (10) :1321-1325
[20]  
BRAWMANMINTZER O, 1993, AM J PSYCHIAT, V150, P1216